<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852238</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2010/03</org_study_id>
    <nct_id>NCT03852238</nct_id>
  </id_info>
  <brief_title>Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)</brief_title>
  <acronym>NoFlic</acronym>
  <official_title>Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver (NoFlic Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to identify direct carcinogenic factors in the absence of
      cirrhosis, and the carcinogenesis pathways involved on nonfibrotic liver (NfCHC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most hepatocellular carcinoma (HCC) complicates cirrhosis, which is often caused by infection
      with hepatitis B or C viruses, alcohol, obesity, exposure to aflatoxin B1 (AFB1) or
      hemochromatosis. Nevertheless, 10 to 40% of HCCs can develop on non-cirrhotic terrain and
      about 5% on nonfibrotic liver (NfHCC). In 20 to 40% of these NfHCCs, no classical HCC risk
      factor is identified. Some cases could be the result of a transformation of an adenoma.
      Others may be associated with yet non-formally identified toxins and / or a specific genetic
      predisposition. While there is a lot of data on alterations of signaling pathways (ß-catenin,
      AKT / mTOR, Ras / pERK, etc.) in &quot;classical&quot; HCCs, altered pathways remain unknown in most
      NfHCCs, even in some cases, activation of β-catenin, inactivating mutations of HNF1 or
      activators of gp130 have been shown. A specific study of NfHCCs, rather rare cancers,
      represents an opportunity to look for directly carcinogenic factors in the absence of
      cirrhosis, and to dissect the involved carcinogenesis pathways.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2010</start_date>
  <completion_date type="Actual">November 14, 2013</completion_date>
  <primary_completion_date type="Actual">November 14, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>exposure to Viral hepatitis B</measure>
    <time_frame>Baseline</time_frame>
    <description>binary yes / undiagnosed by positive serology for anti-HBc antibodies isolated or associated with positive serology for anti-HBs antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>exposure to viral hepatitis C</measure>
    <time_frame>baseline</time_frame>
    <description>binary yes / undiagnosed by positive serology for positive anti-HCV antibodies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>exposure to Alcohol</measure>
    <time_frame>baseline</time_frame>
    <description>binary variable, separating large consumers from others</description>
  </other_outcome>
  <other_outcome>
    <measure>exposure to Exogenous female hormones</measure>
    <time_frame>baseline</time_frame>
    <description>oral contraceptive coded as a binary variable</description>
  </other_outcome>
  <other_outcome>
    <measure>history of liver pathology</measure>
    <time_frame>baseline</time_frame>
    <description>binary variable: yes/no</description>
  </other_outcome>
  <other_outcome>
    <measure>Family history of liver cancer</measure>
    <time_frame>baseline</time_frame>
    <description>binary variable: yes/no</description>
  </other_outcome>
  <other_outcome>
    <measure>Diabetes</measure>
    <time_frame>baseline</time_frame>
    <description>categorical variable (depending on the type of diabetes: 1 or 2).</description>
  </other_outcome>
  <other_outcome>
    <measure>Dyslipidemias</measure>
    <time_frame>baseline</time_frame>
    <description>qualitative variables: hypercholesterolemia / hyper triglyceridemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Medical treatments for dyslipidemia</measure>
    <time_frame>baseline</time_frame>
    <description>depending on the type of medication: statins, fibrates, other</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolic syndrome</measure>
    <time_frame>baseline</time_frame>
    <description>binary variable: present / absent</description>
  </other_outcome>
  <other_outcome>
    <measure>Age of first menstruation</measure>
    <time_frame>baseline</time_frame>
    <description>quantitative variable in years</description>
  </other_outcome>
  <other_outcome>
    <measure>Parity</measure>
    <time_frame>baseline</time_frame>
    <description>number of children</description>
  </other_outcome>
  <other_outcome>
    <measure>breastfeeding</measure>
    <time_frame>baseline</time_frame>
    <description>binary variable : yes / no</description>
  </other_outcome>
  <other_outcome>
    <measure>Menstrual status</measure>
    <time_frame>baseline</time_frame>
    <description>menopausal status will be treated as a binary variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of exposure to different variables</measure>
    <time_frame>baseline</time_frame>
    <description>quantitative variable in months</description>
  </other_outcome>
  <other_outcome>
    <measure>fruits</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of intake assessed by a frequency food questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>vegetables</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of intake assessed by a frequency food questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>meat</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of intake assessed by a frequency food questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>fish</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of intake assessed by a frequency food questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>dairy products</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of intake assessed by a frequency food questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>fats</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of intake assessed by a frequency food questionnaire</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">283</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cases: patients with hepatocellular carcinoma on non-cirrhotic</arm_group_label>
    <description>Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: patients without hepatocellular carcinoma</arm_group_label>
    <description>Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test and self-administrated questionnaires</intervention_name>
    <arm_group_label>Control: patients without hepatocellular carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CASES: patients with a diagnosis of NfHCC with anatomopathological examination and showing
        a HCC according to standard histopathological criteria and an absence of significant
        fibrosis in non-tumoral tissues with the METAVIR system score or equivalent (F0 or F1) or
        the Kleiner et al stage of ASH and NASH (≤stade 2)

        - CONTROLS: patients without NfHCC at baseline
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CASES: patients aged 18 years and older with a diagnosis of NfHCC with
             anatomopathological examination and showing a HCC according to standard
             histopathological criteria and an absence of significant fibrosis in non-tumoral
             tissues with the METAVIR system score or equivalent (F0 or F1) or the Kleiner et al
             stage of ASH and NASH (≤stade 2); signed informed consent; affiliated or beneficiary
             of a social security system

          -  CONTROLS: patients aged 18 years and older without NfHCC at baseline; patients for
             whom an endoscopy is programmed as part of an assessment of intestinal functional
             disorders, dyspeptic disorders or screening colonoscopy or hospitalized patients in
             orthopedic surgery / traumatology or rheumatology departments; signed informed
             consent; affiliated or beneficiary of a social security system

        Exclusion Criteria:

          -  CASES: HCC diagnosed without pathological examination; hepatic transplantation before
             the diagnosis of HCC; patients unable to answer questions; patients who do not speak
             French or live abroad.

          -  CONTROLS: History of liver cancer; other cancers under treatment except cutaneous
             cancers; Colonoscopy indicated in case of familial form of colon cancer; patient with
             cirrhosis; patients unable to answer questions; patients who do not speak French or
             live abroad; Relationship or same home with the case
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civiles de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Villejuif</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>Non-cirrhotic liver</keyword>
  <keyword>Risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

